Kisspeptin-10 vs Sermorelin
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Kisspeptin-10
Kisspeptin-10 is the active fragment of kisspeptin, a hormone that plays a crucial role in initiating puberty and regulating reproductive function. It acts upstream of GnRH in the hypothalamic-pituitary-gonadal axis.
Full details →Sermorelin
Sermorelin is a synthetic analog of GHRH consisting of the first 29 amino acids of the natural hormone. It was previously FDA-approved for GH deficiency diagnosis and treatment in children.
Full details →Side-by-Side Comparison
| Aspect | Kisspeptin-10 | Sermorelin |
|---|---|---|
| Dose Range | 100 mcg–1 mg | 100 mcg–300 mcg |
| Frequency | 1x daily | 1x daily |
| Cycle Length | 1–4 weeks | 8–12 weeks |
| Route | subcutaneous | subcutaneous |
| Mechanism | Binds to KISS1R receptors in the hypothalamus, stimulating GnRH neurons to release GnRH. This triggers the downstream cascade of LH, FSH, and sex hormone production. | Binds to GHRH receptors in the pituitary gland to stimulate natural GH production and release. Maintains the body's natural feedback mechanisms for GH regulation. |
| Typical Dosage | Research protocols vary widely. Studies have used IV boluses of 1-10mcg/kg or subcutaneous administration. Clinical applications still being developed. | Typical dosing: 200-500mcg administered once daily, usually before bed. Some protocols use twice daily dosing. |
| Administration | IV or subcutaneous injection. Has very short half-life requiring frequent administration or continuous infusion for sustained effects. | Subcutaneous injection, preferably at bedtime to work with natural GH release patterns. Can be combined with GHRPs for synergistic effects. |
| Side Effects | Limited data. May cause flushing, increased heart rate, and changes in libido. Generally well-tolerated in studies. | Generally well-tolerated. May cause injection site reactions, headache, flushing, or dizziness. Less side effects than direct GH administration. |
| Best For |
Key Differences
Unique to Kisspeptin-10:
Unique to Sermorelin:
Key Studies
Kisspeptin-10
- Chronic subcutaneous kisspeptin-10 stimulates gonadotropin secretion for 12 days in healthy men.
European journal of endocrinology, 2026
- Kisspeptin-10 Protects Against TNF-α-Induced Chondrocyte Senescence via the SIRT1/p53/p21 Signaling.
Journal of biochemical and molecular toxicology, 2025
- Kisspeptin-10 Ameliorates Obesity-Diabetes with Diverse Effects on Ileal Enteroendocrine Cells and Pancreatic Islet Morphology in High-Fat Fed Female Mice.
Biomolecules, 2025
Sermorelin
- A potentially effective drug for patients with recurrent glioma: sermorelin.
Annals of translational medicine, 2021
- Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?
Clinical interventions in aging, 2006
- Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 1999
Ready to Learn More?
Looking for trusted sources?